Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New device catches debris during heart valve procedure to protect the brain

NCT ID NCT07627984

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a device designed to catch and remove debris that can break loose during transcatheter aortic valve replacement (TAVR), a procedure to replace a narrowed heart valve. The device uses two filters placed in arteries leading to the brain. The trial involved 260 people and measured brain lesions on MRI scans after the procedure. The goal was to see if the device reduces brain injury and improves safety.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
cerebral embolic protection device
What this could lead to
If it works, this device could make TAVR safer by reducing the risk of brain damage from debris during the procedure.
What could go wrong
This is a completed trial with 260 participants, but the device only protects certain brain areas and may not prevent all complications. It is not a treatment for the underlying heart disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

260 people

The number who actually took part.

Started

Sep 2023

Finished

Apr 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥18 years, male or non-pregnant/non-lactating female. 2. Suitable for TAVR and planned to undergo TAVR using an approved transcatheter aortic valve system. 3. TAVR access limited to transfemoral or transapical approach. 4. Imaging-confirmed left common carotid artery diameter of 6.5-10 mm and brachiocephalic artery diameter of 9-15 mm at the site of filter placement. 5. No severe stenosis (\>70%), dilation, dissection, ostial aneurysm, or aneurysm within 3 cm of the aortic origin in the target vessels. 6. Brain imaging evaluable by 3-Tesla magnetic resonance imaging. 7. Willing to comply with protocol-required follow-up assessments. 8. Written informed consent provided by the subject or legal guardian. Exclusion Criteria: 1. Impaired right upper limb blood flow. 2. Intracranial hemorrhage, stroke, or transient ischemic attack within 6 months before procedure. 3. Acute myocardial infarction within 1 month before procedure. 4. Calcification in the intended filter deployment region. 5. Planned pacemaker or defibrillator implantation within 30 days after TAVR. 6. Left ventricular ejection fraction ≤20%. 7. Infective endocarditis, intracardiac/aortic mass, thrombus, or vegetation on echocardiography. 8. Severe occlusive carotid disease requiring concomitant carotid intervention, or carotid stenting/endarterectomy within 6 weeks. 9. Leukopenia, acute anemia, thrombocytopenia, bleeding diathesis, or coagulation disorder. 10. Active peptic ulcer disease or gastrointestinal bleeding within 3 months. 11. Severe allergy or known contraindication to nitinol, stainless steel alloy, or contrast media. 12. Contraindication to antiplatelet and/or anticoagulation therapy, or refusal of blood transfusion. 13. Severe renal insufficiency (serum creatinine \>3.0 mg/dL, eGFR \<30 mL/min, or need for renal replacement therapy). 14. Known psychiatric disease or substance abuse that may interfere with compliance or data interpretation. 15. Life expectancy \<1 year. 16. Active infection requiring concurrent antibiotic therapy. 17. Other clinical conditions preventing compliance with the instructions for use of the investigational device. 18. Concurrent use or planned use of another investigational device or drug during the study period. 19. Severe tortuosity of right upper extremity vessels or inability to accommodate a 6 F sheath. 20. Contraindication to MRI, including implanted pacemaker/defibrillator, metal implants, metal fragments, clips, or intracranial/ocular implanted devices.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Aortic valve stenosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Xiamen Cardiovascular Hospital Xiamen University

    Xiamen, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.